India Fat-Loss Drug Sales Slow After Early Spike From Generics

Growth in India’s obesity- and diabetes-drug market is losing steam just months after a surge triggered by the arrival of generic semaglutide products.

To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.